Larimar Therapeutics: The Market Is Mispricing A Potential Standard Of Care
Source: SeekingAlpha
2026-01-16 06:17:31 ET
I don't usually spend my time digging through clinical-stage biotechs. My typical picks are undervalued shippers or mispriced subprime lenders where you can touch the assets or model the cash flows with some degree of certainty. But occasionally, a setup comes along that is so disconnected from the underlying science and the large unmet medical need it addresses that it's hard to ignore....
Read the full article on Seeking Alpha
For further details see:
Larimar Therapeutics: The Market Is Mispricing A Potential Standard Of Care
Larimar Therapeutics Inc.
NASDAQ: LRMR
LRMR Trading
-7.36% G/L:
$4.595 Last:
1,914,421 Volume:
$4.87 Open:
LRMR Latest News
March 04, 2026 04:05:00 pm
Larimar Therapeutics to Participate in Upcoming Investor Conferences in March
February 25, 2026 08:59:46 pm
Larimar Therapeutics Announces Pricing of Upsized $100 Million Underwritten Public Offering
February 25, 2026 04:01:00 pm
Larimar Therapeutics Announces Proposed $75 Million Underwritten Public Offering
February 24, 2026 07:56:05 pm
$38M Defense Backlog vs. $6M Market Cap, Breakthrough Biotech Data, and the Quantum Security Land Grab
LRMR Stock Data
$285,016,005
38,430,086
1.32%
48
N/A
Biotechnology & Life Sciences
Healthcare
US
Bala Cynwyd
